tiprankstipranks
Trending News
More News >
Biotest (0N6Z) (DE:BIO)
:BIO
Advertisement

Biotest (BIO) AI Stock Analysis

Compare
5 Followers

Top Page

DE:BIO

Biotest

(LSE:BIO)

Rating:51Neutral
Price Target:
€39.00
▲(0.00%Upside)
Biotest's overall stock score is driven by mixed financial performance with strengths in balance sheet stability and cash flow improvements, but offset by operational inefficiencies and inconsistent profitability. Technical analysis indicates bearish momentum, while valuation metrics raise concerns due to a negative P/E ratio, despite a high dividend yield.

Biotest (BIO) vs. iShares MSCI Germany ETF (EWG)

Biotest Business Overview & Revenue Model

Company DescriptionBiotest (BIO) is a global biopharmaceutical company that specializes in the development, production, and marketing of plasma protein products and biological drugs. Operating in the healthcare and biotechnology sectors, Biotest offers a range of products primarily aimed at treating blood disorders, immune system deficiencies, and other critical health conditions. The company's core product portfolio includes immunoglobulins, coagulation factors, and albumins, which are vital for patients with rare and chronic diseases.
How the Company Makes MoneyBiotest makes money through the sale of its plasma protein products and biological drugs. The company's revenue model is largely based on the collection of human plasma, which is then processed into a variety of therapeutic products. These products are distributed and sold to hospitals, healthcare providers, and pharmaceutical companies worldwide. Key revenue streams include the sales of immunoglobulins for immune deficiencies, coagulation factors for hemophilia, and albumins for volume replacement therapies. Additionally, Biotest may engage in strategic partnerships and collaborations with other pharmaceutical companies to enhance its product offerings and expand its market reach, further contributing to its earnings.

Biotest Financial Statement Overview

Summary
Biotest shows balanced financial performance with a stable balance sheet and improved cash flows. However, there are challenges in maintaining consistent profitability due to operational inefficiencies.
Income Statement
65
Positive
Biotest's income statement shows a mixed performance. Gross Profit Margin improved to 30.82% in the latest year, coupled with a positive Net Profit Margin of 3.63%, indicating moderate profitability. However, the company experienced a significant drop in Gross Profit from the previous year, suggesting volatility in profit generation. Revenue growth from 2023 to 2024 was 6.08%, which is positive but marked by a decline in EBIT and EBITDA margins, indicating rising operational costs or inefficiencies.
Balance Sheet
72
Positive
The balance sheet of Biotest indicates a stable financial position. The Debt-to-Equity Ratio stands at 1.13, reflecting a balanced capital structure. Return on Equity is modest at 4.97%, showing moderate returns to equity holders. The Equity Ratio of 37.00% suggests a strong equity base relative to total assets, enhancing financial stability. However, the increase in total debt over time could pose potential risks if not managed well.
Cash Flow
70
Positive
Biotest's cash flow statements reveal stable cash flow management. Operating Cash Flow to Net Income Ratio is 2.31, indicating strong cash generation relative to net income. Free Cash Flow improved significantly to a positive $32.2 million in 2024 from a negative position in the prior year, suggesting robust cash flow improvement. However, the fluctuation in free cash flow growth over the years denotes potential instability in cash generation capability.
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Biotest Technical Analysis

Technical Analysis Sentiment
Negative
Last Price39.00
Price Trends
50DMA
41.78
Negative
100DMA
41.84
Negative
200DMA
41.63
Negative
Market Momentum
MACD
-0.34
Positive
RSI
41.50
Neutral
STOCH
22.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Negative. The current price of 39 is below the 20-day moving average (MA) of 41.61, below the 50-day MA of 41.78, and below the 200-day MA of 41.63, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 41.50 is Neutral, neither overbought nor oversold. The STOCH value of 22.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:BIO.

Biotest Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
€1.35B39.2717.48%0.75%15.89%14.62%
76
Outperform
$313.21M20.822.99%5.62%-21.87%
65
Neutral
€6.45B18.49-1.30%2.20%-0.15%-41.32%
62
Neutral
€535.23M5.89-26.06%-10.32%-250.76%
51
Neutral
€1.37B64.15-4.72%0.10%-18.82%-113.85%
46
Neutral
€1.32B-20.51%1.50%-127.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:BIO
Biotest
39.00
-3.00
-7.14%
DE:EVT
Evotec
7.44
-1.17
-13.54%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
66.60
28.80
76.19%
DE:ILM1
Medios AG
12.68
-5.32
-29.56%
DE:FYB
Formycon AG
30.15
-22.05
-42.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 26, 2025